Robert Den,

Robert Den, MD, is the chief medical officer (CMO) of Alpha Tau and has been with the company since 2019. He has a strong background in radiation oncology, urology, and cancer biology from Thomas Jefferson University. Den attended Yale University for his undergraduate studies and trained in medical school at Harvard College and MIT in a joint program. Prior to joining Alpha Tau, he ran a lab and clinical trials. Since his appointment as CMO in 2019, Den has focused on bringing Alpha Tau products to market. He recently spoke with Dermatology Times to discuss the mechanisms of Alpha DaRT and its potential role in the future of dermatology and skin cancer treatment.

Biography:  https://www.dermatologytimes.com/view/robert-den-md-exploring-the-potential-of-alpha-dart-in-skin-cancer

94%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

  • Robert Den appears to have a strong and unbiased understanding of Alpha DaRT and its potential in cancer treatment.

Conflicts of Interest

100%

Examples:

  • Den attended Yale University for undergraduate studies and trained in medical school at Harvard College and MIT in a joint program.
  • Prior to working with Alpha Tau, Den ran a lab and clinical trials.

Contradictions

85%

Examples:

  • Approximately 1 in 5 Americans will develop skin cancer in their lifetime.
  • Radiation therapy can produce uncomfortable or painful side effects.
  • Skin cancer rates are rising due to better detection methods and increased sun exposure.

Deceptions

80%

Examples:

  • Providers are now serving in an era where there is an opportunity to provide patients with more options than ever before.
  • The primary goal of all treatments is to eradicate cancer, but providers are now in a position to consider the patient’s quality of life when determining a path forward.

Recent Articles

New Non-Surgical Treatment for Skin Cancer: IG-SRT and Advancements in Systemic Therapy

New Non-Surgical Treatment for Skin Cancer: IG-SRT and Advancements in Systemic Therapy

Broke On: Thursday, 06 June 2024 New treatment options for skin cancer include Image-Guided Superficial Radiotherapy (IG-SRT), a non-surgical method using low level radiation that's less invasive and leaves the skin intact. Advancements in systemic therapy, such as immunotherapy and targeted therapies, have revolutionized melanoma treatment, increasing median survival from 6 months to nearly 6 years for inoperable stage IV disease. Wearing high SPF sunscreen is crucial for preventing skin cancer and protecting against wrinkles and discoloration.